LAURUSLABS2024-10-012024-12-31 LAURUSLABS2024-10-012024-12-31 LAURUSLABS2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member LAURUSLABS2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member LAURUSLABS2024-12-31 LAURUSLABS2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member LAURUSLABS2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member LAURUSLABS2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member LAURUSLABS2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss02Member LAURUSLABS2024-10-012024-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member LAURUSLABS2024-10-012024-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 540222 LAURUSLABS NOTLISTED Laurus Labs Limited Equity 2024-04-01 2025-03-31 2025-01-24 2025-01-06 INR Crores Third quarter 14:00:00 14:40:00 2025-01-24 2025-01-24 Not applicable Single segment Manufacturer of Generics API, Generics FDF, Ingredients and Synthesis 2024-10-01 2024-12-31 Unaudited Consolidated 14150500000.00 94200000.00 14244700000.00 6530000000.00 347900000.00 -776400000.00 1891200000.00 578000000.00 1060900000.00 3306300000.00 12937900000.00 1306800000.00 0.00 1306800000.00 349700000.00 51000000.00 400700000.00 0.00 906100000.00 0.00 0.00 0.00 23300000.00 929400000.00 -14700000.00 914700000.00 923000000.00 6400000.00 908300000.00 6400000.00 1078500000.00 2 1.71 1.71 0.00 0.00 1.71 1.71 0.00 0.00 0.00 1. The above consolidated unaudited financial results of Laurus Labs Limited ( the Company ) including its subsidiaries (Collectively known as the Group ) , its associates and joint venture (as mentioned in note 3) has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on January 24, 2025. The statutory auditors of the Company have carried out a limited review on consolidated financial results and have issued an unmodified conclusion in respect of the limited review for the quarter and nine months ended December 31, 2024. 2. These consolidated financial results of the Group have been prepared in accordance with the Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act, 2013 ( the Act ) read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ( SEBI ). 3. The consolidated financial results include the results of the following entities: 4. a) During the quarter ended December 31, 2022, the Parent Company incorporated wholly owned subsidiary, Laurus Specialty Chemicals Private Limited (LSCPL) in India on December 01, 2022. LSCPL has not commenced its operations. b) During the quarter, Laurus Bio Private Limited ( Laurus Bio ) entered into definitive agreement with Laurus Labs Limited (Parent Company), Eight Roads Ventures and F-Prime Capital ( Investors ). Pursuant to this agreement, Eight Roads Ventures and F-Prime Capital have infused Rs. 120 Crores into Laurus Bio. c) Pursuant to the joint venture agreement for KRKA Pharma Private Limited ( KRKA ), entered into by the Laurus Labs Limited (Parent Company) with KRKA, d.d., Novo mesto, Capital contributions of Rs. 45 Crores have been made into KRKA during the quarter. Parent Company made a Contribution of Rs. 22.05 Crores for 49% stake. The Parent Company has accounted for the investment in KRKA as joint venture w.e.f. October 03, 2024. KRKA has not commenced its operations. 5. The Group is engaged in the manufacture and sale of Pharmaceuticals which constitutes a single reportable business segment as per Ind AS 108 - 'Operating Segments'. 6. During the quarter ended December 31, 2024, the Parent Company allotted 93,177 equity shares of Rs 2/- each, consequent to the exercise of the stock options by the employees of the Company under the Employee Stock Option Scheme. Single segment 2024-04-01 2024-12-31 Unaudited Consolidated 38336600000.00 165300000.00 38501900000.00 18022200000.00 830500000.00 -1899700000.00 5418200000.00 1596000000.00 3196600000.00 9618600000.00 36782400000.00 1719500000.00 0.00 1719500000.00 765600000.00 -251500000.00 514100000.00 0.00 1205400000.00 0.00 0.00 0.00 50300000.00 1255700000.00 -15800000.00 1239900000.00 1246500000.00 9200000.00 1230700000.00 9200000.00 1078500000.00 2 2.31 2.31 0.00 0.00 2.31 2.31 0.00 0.00 0.00 Other expenses 3306300000.00 Other expenses 9618600000.00 (i) Remeasurement gains/(losses) on defined benefit plans 3800000.00 ii) Income tax relating to items that will not be reclassified to profit n or loss in subsequent periods -1000000.00 (i) Remeasurement gains/(losses) on defined benefit plans 11400000.00 ii) Income tax relating to items that will not be reclassified to profit n or loss in subsequent periods -2900000.00 2800000.00 8500000.00 0.00 0.00 Exchange differences on translating the financial statements of foreign operations -17500000.00 Exchange differences on translating the financial statements of foreign operations -24300000.00 -17500000.00 -24300000.00 0.00 0.00